<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945424</url>
  </required_header>
  <id_info>
    <org_study_id>QIV08</org_study_id>
    <secondary_id>U1111-1143-8433</secondary_id>
    <nct_id>NCT01945424</nct_id>
  </id_info>
  <brief_title>Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry</brief_title>
  <official_title>Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a
      prospectively recruited pregnancy surveillance program designed to collect and analyze
      information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women will be enrolled in the registry prospectively (after exposure to QIV in
      routine clinical settings but before knowledge of the pregnancy outcome). Women exposed to
      QIV with or without adverse events will be recorded in the Global Pharmacovigilance Database
      and medically reviewed. Pregnancy outcomes will be sought via questionnaires sent to the
      reporter at enrollment, estimated time of delivery, and six months after delivery.
      Descriptive statistical methods will be the primary approach for summarizing data.

      No vaccine products will be provided or administered as part of this registry protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2013</start_date>
  <completion_date type="Actual">September 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 15, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Months</target_duration>
  <primary_outcome>
    <measure>Number of cases and outcomes of pregnancies following exposure to QIV vaccine</measure>
    <time_frame>Up to six years</time_frame>
    <description>Data will be summarized using descriptive statistical methods and stratified by pregnancy outcome (spontaneous abortion, elective termination, fetal death/stillbirth, live birth) and timing of vaccine exposure. Infant outcomes include birth defects and physical and social development.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">244</enrollment>
  <condition>Pregnancy</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Pregnancy Cases</arm_group_label>
    <description>Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Influenza Vaccine (QIV)</intervention_name>
    <description>No Intervention as part of this protocol</description>
    <arm_group_label>Pregnancy Cases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women will be enrolled in the registry prospectively (after exposure to
             Quadrivalent Influenza Vaccine (QIV) but before the conduct of any prenatal tests that
             could provide knowledge of the outcome of pregnancy). If the condition of the fetus
             has already been assessed through prenatal testing (e.g., targeted ultrasound,
             amniocentesis, etc.), such reports will be considered retrospective reports.
             Retrospective reports are also eligible for the registry but they will be analyzed
             separately from prospective reports.

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofipasteurpregnancyregistry.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2013</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quadrivalent Influenza Vaccine</keyword>
  <keyword>Pregnancy Registry</keyword>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

